August 12, 2019
Liver Damage More Commonly Due to Malignant Tumors than Cancer Immunotherapy Drug
Robert Fontana, MD discusses his recent study that looked at the incidence of liver injury associated with pembrolizumab therapy.
Robert Fontana, MD discusses his recent study that looked at the incidence of liver injury associated with pembrolizumab therapy.